Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IMRX Immuneering Corp
- Stocks
- Healthcare
- NASDAQ: IMRX
Price (delayed)
$1.44
Market cap
$51.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.97
Enterprise value
$20.04M
Highlights
The debt has declined by 7% year-on-year
The quick ratio has decreased by 49% YoY but it has increased by 46% from the previous quarter
The EPS is down by 5% year-on-year but it is up by 3.4% since the previous quarter
Immuneering's equity has decreased by 47% YoY
The net income has declined by 14% year-on-year
Key stats
What are the main financial stats of IMRX
Market
Valuations
Earnings
Shares outstanding
35.99M
Market cap
$51.82M
Enterprise value
$20.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$64.23M
Net income
-$61.77M
EBIT
-$61.77M
EBITDA
-$61.07M
Free cash flow
-$53.65M
Per share
Balance sheet
Liquidity
EPS
-$1.97
EPS diluted
-$1.97
Free cash flow per share
-$1.51
Book value per share
$1.17
Revenue per share
$0
TBVPS
$1.23
Total assets
$50.68M
Total liabilities
$8.84M
Debt
$4.08M
Equity
$41.84M
Working capital
$33.1M
Debt to equity
0.1
Current ratio
7.48
Quick ratio
7.02
Net debt/EBITDA
0.52
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-99.2%
Return on equity
-119.2%
Return on invested capital
-718.2%
Return on capital employed
-135.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMRX stock price
How has the Immuneering stock price performed over time
Intraday
12.06%
1 week
26.32%
1 month
15.2%
1 year
-6.49%
YTD
-34.55%
QTD
-5.26%
Financial performance
How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$64.23M
Net income
-$61.77M
Gross margin
N/A
Net margin
N/A
The net income has declined by 14% year-on-year
The operating income has declined by 9% year-on-year
Price vs fundamentals
How does IMRX's price correlate with its fundamentals
Growth
What is Immuneering's growth rate over time
Valuation
What is Immuneering stock price valuation
P/E
N/A
P/B
1.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 5% year-on-year but it is up by 3.4% since the previous quarter
Immuneering's equity has decreased by 47% YoY
IMRX's P/B is 3.3% more than its last 4 quarters average of 1.2
Efficiency
How efficient is Immuneering business performance
The ROE has plunged by 114% YoY and by 19% from the previous quarter
The ROA has dropped by 96% year-on-year and by 16% since the previous quarter
IMRX's return on invested capital is down by 22% since the previous quarter
Dividends
What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMRX.
Financial health
How did Immuneering financials performed over time
The quick ratio has decreased by 49% YoY but it has increased by 46% from the previous quarter
The current ratio has declined by 48% year-on-year but it has increased by 42% since the previous quarter
The debt is 90% smaller than the equity
IMRX's debt to equity has surged by 67% year-on-year
Immuneering's equity has decreased by 47% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.